Library

Place of publication:
New therapeutic journal Non Nocera, December, 2020

Resume:
asthenia (Greek “powerlessness”, “lack of strength”)-a protective-compensator reaction of the body to any state that threatens the exhaustion of energy resources, and by definition in ICD-10-“a constant sensation and/or complaints about a sense of general weakness, increased fatigue (with any type of load), as well as a decrease in working capacity in combination with 2 or more of the following complaints: muscle pain; headaches of tension; dizziness; sleep disturbances; dyspepsia; inability to relax; irritability".

Clinical manifestations of asthenic syndrome (AS) can be divided into:

• physical (muscle weakness, fatigue, exhaustion);

• emotional-psychological (emotional lability, irritability, a sense of internal tension, lowered mood background, apathetic);

• cognitive (decrease in mental performance, memory, concentration of attention);

• Sleep disorders (insomnia, drowsiness).

Place of publication:
New therapeutic magazine "Non Nocera", November, 2020

Summary:
arterial hypertension (AH) is an important medical and social problem around the world. The disease is often called the "silent killer" (English Silent Killer, since most patients are quite difficult to suspect the earliest symptoms of the lesions of target organs mediated by AH. Moreover, in patients with systolic blood pressure (garden)> 130 mm RT. Art. In the middle age, the risk of dementia in old age increases by 34%. According to the current clinical recommendations, the manifestations of the brain damage to AH are considered to be the so-called dumb (asymptomatic) lacunar heart attacks, hyperinathery changes in the white substance of the brain and cerebral micro-power, which are detected by magnetic resonance tomography (MRI). The clinical manifestation of brain damage as a target organ is cognitive impairment (KN). The recommendations for the treatment of patients from AH 2018 emphasize that MRI is an enough examination method, which does not allow it to use it for routine screening. However, neuroizualization, that is, an MRI, is necessary for patients with clinical signs of cognitive disorders (KF). Consequently, a competent and timely detection of cognitive complaints, signs of KN and their correction in patients with AH is an extremely important task for a doctor of any specialty.

Place of publication:
therapy No. 6 (40) 2020

Summary:
the purpose of the study is to evaluate the effectiveness, safety and the possibility of correcting the neuropsychiatric manifestations of chronic brain ischemia (chemical) drugs Mexidol ^® and Mexidol ^® Forte 250 within the framework of consecutive therapy against the background of arterial hypertension, atherosclerosis (IBS), osteoarthritis or OA) or OA) or OA) rheumatoid arthritis (RA). Material and methods. 134 patients 45–75 years old with a neuroimulated chemical chemicized, combined with hypertension, coronary heart disease and articular pathology were examined. Group 1 (observations) included 79 patients - 30 patients with RA (subgroup 1A) and 49 with the ot of the knee joints (subgroup 1b), who received in the complex therapy Mexidol ^® and Mexidol ^® Fort 250. Group 2 (control) amounted to 55 patients - 25 patients with RA (subgroup 2A) and 30 - with OA (subgroup 2B), which used to use basic therapy without the addition of Mexidol. The dynamics of subjective and physical symptoms were evaluated, values ​​on the scales of CGI, Mosa, MFI 20, anxiety and depression of Hamilton, Tinnetti. Mexidol ^® was prescribed intravenously (500 mg per day) for 14 days with the subsequent oral administration of the drug Mexidol ^® Fort 250 at 250 mg 3 times/day another 60 days. Results. ^® and Mexidol ^® to the standard treatment of drugs in the framework of consistent therapy contributed to an increasing improvement in all studied indicators. In the control groups, the cognitive status did not change. The use of initiating intravenous therapy with Mexidol increased the adherence of patients to the prolonged use of the drug. Conclusion. Violations of the locomotor function in polymorbid patients are partially associated with chemicals. The additional purpose of the consistent infusion and tablet forms of Mexidol significantly improves cognitive functions with the correction of the stability of walking, asthenic manifestations, and increases the motivation for active life. Key words: chronic brain ischemia, Mexidol ^® , Mexidol ^® Fort 250, osteoarthritis, rheumatoid arthritis, arterial hypertension, coronary heart disease.

Place of publication:
Infectious diseases, 2020, T. 18, No. 2, P. 97–102

Summary:
The article presents a review of the data that with a disease caused by COVID-19, along with impaired respiratory functions of the lungs (bronchoalveolar epithelium does not withheld oxygen, etc.), the level of hemoglobin and its ability to transfer oxygen to organs and tissues of the body, it decreases, the level of hema rises; Anokemia, oxygen starvation of organs and tissues of the whole organism and oxidative stress develops. Mexol, which was created in Russia, is widely used in medical practice, including diseases accompanied by ischemia and hypoxia. Mexol has an antihypoxic, antioxidant effect, the ability to restore mitochondrial respiratory dysfunction and, thus, affects key, basic processes in the cellular structures of the body and tissues of the body that occur in various hypoxic conditions. Mexidol can be useful in the complex therapy of patients with COVID-19. Key words: Covid-19, antioxidant, antihypoxant, hemoglobin, hypoxia, oxygen starvation, mexidol, mitochondrial dysfunction, oxidative stress.

Place of publication:
New therapeutic journal "Non Nocera" No. 4, 2019

Summary:
acute respiratory diseases or, as it is customary to name them, acute respiratory infections (Ori) is an urgent problem of modern medicine, especially during periods of sharp fluctuations in the temperature and humidity of the environment, when the traditionally expected incidence of influenza and other visual or mixtures increases sharply .

Place of publication:
therapeutic archive, 1, 2015

Summary:
the prevalence of diabetes (diabetes) of the 2nd type and metabolic disorders preceding it reached the scale of the epidemic. Oxidative stress plays a significant role in the development of micro- and macro-vascular complications in patients with diabetes. The accumulation of free radicals is responsible for the activation of pathological biochemical ways responsible for the development of systemic and vascular inflammation, endothelial dysfunction, hypercoagulation and ischemic conditions. Since damage to the vascular and nervous systems is not leveled even with adequate control of glycemia, comprehensive pathogenetic treatment strategies are needed. One of the mandatory components of the complex therapy of complications of diabetes is the use of antioxidant therapy using the drug Mexidol.

Place of publication:
therapy No. 8 (70) 2023

Summary:
Annotation. Chronic brain ischemia (Khim) is one of the most common neurological pathologies. Its development is affected by many factors, among which arterial hypertension (AH) occupies a special place. Him contributes to cognitive impairment, negatively affects the quality of life and leads to motor and psycho -emotional disorders. In the aspect of the therapy of this condition, an important role belongs to neuroprotectors and, in particular, the use of ethylmethylhydroxypyridine of succinate (Mexol ^® , NPK Pharmasoft LLC, Russia), which has a multimodal effect and confirms its high efficiency in a large number of clinical studies. The evidence base of ethylmethylhydroxypyridine of the succinate, including in the study of Memo, indicates the particularly high effectiveness of the drug among patients with Khim and AG: they have Mexol ^® significantly improves cognitive functions, reduces the level of anxiety and asthenia and improves the quality of life. With this in mind, the drug can be recommended for use in complex therapy of chemicals, especially in patients with AG. Keywords: chronic brain ischemia, ethylmethylhydroxypyridine succinate, Mexidol ^® , arterial hypertension, cognitive functions.

Place of publication:
New therapeutic magazine "Non Nocera", May 2024

Summary:
Cerebrovascular diseases (CVP) retain in the modern world a leading position in the rating of the incidence and disability of the population of most countries. Metabolic disorders, being important risk factors for the development of CVP, are also widespread in populations regardless of gender and age. The frequent combination of CVP and metabolic disorders, including somatic and abdominal obesity, insulin resistance, hyperinosulinemia, hyperglycemia and dyslipidemia, is a bridgehead for the rapid development of complications. One of the early manifestations of such a comorbid union is the formation of vegetative disorders. It is known that vegetative disorders are most often secondary, that is, they arise against the background of existing somatic or mental diseases, but can also develop when exposed to psychogenic factors (stress reaction, adaptation disorders, psychosomatic diseases, anxious and depressive disorders). The most common causes of the development of autonomic dysfunction are organic diseases of the nervous system and somatic diseases, including metabolic and hormonal.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2024, T. 124, No. 4

Summary:
Purpose of the study. Assessment of the effect of the pharmacological modulation of the rehabilitation process with Mexidol with a rehabilitation component of the rehabilitation treatment of cognitive-emotional disorders in patients who have undergone acute cerebral deficiency (scenario) due to acute cerebrovascular impairment or cranial-brain injury. Material and methods. A randomized intervention prospective study was carried out, which consisted of 5 visits. Patients are divided into main groups (OG, N = 30, received standard therapy and Mexidol in/B 500 mg/day 10 days with the subsequent prescription of the drug Mexidol Forter 250, orally, 1 tablet 3 times a day 8 weeks) and comparison (GS, N = 30, received only standard therapy for 66 days). Results. The OG has a comparable to the HS improvement of cognitive functions (p <0.001) (in both groups, improving the results of the Schulte test according to the criteria “Effectiveness of Work” and “The total execution time”, on the Moca scale (for visit 5 - 23.8 ± 2, 6 and 22.9 ± 3.0 points, p = 0.227)). The significant superiority of the OG over the GS is shown in terms of such indicators as a decrease in the severity of anxiety (HADS scale), a visit 4 - 2.6 ± 2.4 versus 4.4 ± 2.4 points (p = 0.004), and depression (Beka scale) , visit 3 - 7.5 ± 4.5 versus 11.4 ± 5.6 points (p = 0.005). The tendency of the superiority of the OG according to muscle power (MRC scale), a visit 4 - 3.3 ± 5.1 versus 2.1 ± 2.2 points (p = 0.051) and the level of vital activity (according to RM), a visit 5 - 2, 9 ± 0.7 versus 3.3 ± 0.6 points (p = 0.053). The statistically significant increase in the mobility of the patients of the OG compared to the GS (the difference in the values ​​of the Rivermid index is 5 - 10.3 ± 2.8 and 8.0 ± 2.8 points, p = 0.006), the average increase in the Rivermide index for visits 5 - 5.4 ± 2.1 versus 3.4 ± 1.6 points (p <0.001). The decrease in the points of the consequences of intensive care (Pets) in both groups was revealed, the statistically significant decrease in the severity of Pits in relation to the previous visit was revealed only in OG (p <0.001). The OG also determined the best, compared to control, indicators of the dynamics of systolic velocity of cerebral blood flow and overshoot coefficient. The study did not record undesirable phenomena (nya). Conclusion. A positive modulating effect of Mexidol was demonstrated with respect to accelerating the restoration of tolerance to cognitive loads, improving the psycho -emotional background by reducing symptoms of anxiety and depression and secondary improvement of motor rehabilitation results in the early recovery period in patients who suffered the scenes, including with Pets manifestations. During the study, Nyu and significant differences in vital functions are not registered, which indicates the comparable safety of therapy in OG and HS. Keywords: acute cerebral failure, Mexidol, ethylmethylhydroxypyridine succinate, Bek scale, modulating effect, Mexidolneuro2023.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2024, T. 124, No. 3, Issue. 2

Summary:
ischemic stroke (AI) is an acute life -burning state, its outcome is determined by the degree of damage to brain tissue, the quality and rate of medical care in the first minutes and hours of the disease. An important mechanism for damage to brain tissue both with ischemia and reperfusion is oxidative stress. The review considers the adverse effect of oxidative stress with ischemia and brain reperfusion of AI. The results of preclinical studies are presented that demonstrate the ability of Mexidol to eliminate the effect of free radicals, to activate antioxidant protection. The data of clinical studies of the use of Mexidol in combination with thrombolytic therapy in patients with AI are considered. Key words: ischemic stroke, revascularization, oxidative stress, Mexidol.

Place of publication:
Medical alphabet, 2023, No. 21

Summary:
Purpose of the study. To study the effect of Mexidol ^® and Mexidol ^® Fort 250 on cognitive status of patients with post -shoe syndrome. Material and methods. 112 patients aged 24–60 years (55 men and 57 women) were examined, which were divided into two groups: the main one - 76 people with a confirmed coronaviral infection with symptoms that served as the basis for the diagnosis of post -icing syndrome (PKS), and control control - 36 people who have not painted coronavirus infection. Patients underwent a neurological and general somatic examination. For the study of cognitive functions, a brief scale for assessing the mental status (Mini Mental State Examination, MMSE) and a battery of tests for evaluating frontal dysfunction (Frontal Assessment Battle) was used. Memory was evaluated by the results of the subtest “memory” of khops, tests “10 words” and visual memory. The level of attention was investigated by the Schulta test and in the test “Verbal associations”, visual-spatial functions were evaluated using the clock test test. To correct the identified disorders, Mexidol ^® according to the scheme 500 mg times a day daily intravenously for 14 days with the subsequent transition to Mexidol Fort ^® 250 to 750 mg per day (one tablet 250 mg three times a day) for 2 months. Results. Patients with post -shoe syndrome were characterized by cognitive heterogeneity: in the structure of cognitive disorders they had lungs (46.0 %) and moderate (36.8 %) cognitive disorders. The course of treatment with Mexidol led to a decrease in the severity of the cognitive symptoms of the PKS. High efficiency and safety of prolonged sequential therapy with Mexidol (injections, then the tablet form Mexidol ^® Forte 250). Keywords: post-shoe syndrome, coronavirus infection SARS-COV-2 New, Cognitive Disorders, Mexidol ^® .

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2023, T. 123, No. 5

Summary:
Purpose of the study. To evaluate the effectiveness of consistent therapy with Mexidol and Mexidol Fort 250 in the correction of post -shoe syndrome (PKS) in patients with chronic cerebrovascular diseases (HCVZ). Material and methods. An analysis of the results of the examination and treatment of 110 patients with the CCVZ who suffered Covid-19 was carried out. Patients of the main group (OG, N = 55) received Mexidol (5 ml of iv in a drip for 14 days with the subsequent transition to the tablet form of Mexidol Fort 250, 1 tablet 3 times a day for 2 months); 55 patients of the comparison group (GS) did not receive antioxidants. All included in the study of patients conducted an MRI examination and detailed neuropsychological testing. Results. Patients have a significant improvement in the state of cognitive functions, the regression of asthenia symptoms, and the improvement of night sleep. Differences were statistically significant in comparison with both the initial level and with the GS. Conclusion. The appointment of the drug does not require age -related dose correction and goes well with basic therapy. The recommended scheme for the use of Mexidol: 14 days for 5 ml of iv or/m, then taking the drug Mexol Forter 250 in a dose of 1 tablet 3 times a day for 2 months. Key words: chronic cerebrovascular diseases, post -shoe syndrome, Mexidol, treatment.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2023, T. 123, No. 4

Summary:
Purpose of the study. To study the clinical and psychological profile and the quality of life of patients with post-shoe syndrome (PKS). Material and methods. 162 patients aged 24-60 years with a confirmed coronary reerovirus infection caused by the SARS-COV-2 virus, having symptoms that were the basis for the diagnosis of PKS, were examined. Patients underwent a neurological and general somatic examination with the identification of the corresponding neurological syndromes. They evaluated the intensity and nature of the pain (Mc Gill questionnaire), the level of psychosocial stress (Holmes-Road questionnaire), the severity of asthenia (the MFI-20 scale), the level of anxiety (Spielberger-Khanin questionnaire), depression (Bek scale). The quality of life was carried out by applying the Russian version of the SF-36 questionnaire. To correct the identified disorders, Mexidol was used 500 mg once a day every day in/in drip for 14 days, followed by the Mexidol Fort 250, 1 tablet 3 times a day for 2 months. Results . The course of treatment with Mexidol of patients with a PKS led to a decrease in the severity of subjective and objective symptoms of the PKS, asthenic, anxious and depressed disorders, and improved the quality of life of patients. Conclusion. The high efficiency and safety of consistent therapy with Mexidol (V/V, then orally Mexidol Forte 250) in patients with PKS are shown. Key words: post-shoe syndrome, coronavirus infection SARS-COV-2, emotional disorders, anxiety, depression, quality of life, Mexidol.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2023, T. 123, No. 3, Issue. 2

Summary:
Covid-19 development is associated with damage to various organs and systems of the body, including the development of acute ischemic stroke (AI). The article discusses modern ideas about the pathogenesis of AI at the Covid-19. The data on the choice of optimal therapy of patients with COVID-19 and acute AI, as well as the possibility of increasing the efficiency of rehabilitation measures, are analyzed. Information about the effectiveness of the use of the drug Mexidol in patients with COVID-19 and AI is given. Key words: ischemic stroke, Covid-19, treatment, rehabilitation, Mexidol.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2022, T. 122, No. 3

Summary:
the problem of post -shoe syndrome (PKS) attracts great interest due to the widespread prevalence and diversity of clinical manifestations. The main neurological manifestations of the PKS are considered. Information is given about the alleged mechanisms of the formation of PKS. The possibility of using the drug Mexidol for the treatment of patients with PKS is discussed. Key words: Covid -19, post -shoe syndrome, cognitive disorders, chronic brain ischemia, Mexidol, treatment.

Place of publication:
New therapeutic magazine "Non Nocera", November 2021

Summary:
A study of the effectiveness of the use of Mexidol in patients with COVID-19 amid chronic brain ischemia was carried out in St. Petersburg based on St. Petersburg GBUZ “City Hospital No. 38 named after N. A. Semashko. " 304 patients with HIGM and Covid-19 were observed; The 1st group (n = 152) was compiled by patients who received basic therapy and Mexidol, the 2nd group (n = 152) - received only basic therapy. For 14 days, Mexidol was prescribed intravenously with a drop of 500 mg (10 ml) per 400 ml of physiological solution, then Mexol Forte 250 was prescribed 1 tablet (250 mg) 3 times a day for 2 months. They evaluated the state of cognitive functions (Mosa scale), sleep (Spiegel questionnaire), asthenia (MFI-20 scale), quality of life (SIP questionnaire). The examination was carried out before the start of treatment, 30 and 75 days after its beginning. According to the results of the study, in patients in the administration of the drug Mexidol, there were more complete and early restoration of the state of cognitive functions (increase in indicators on the Mosa scale), regression of asthenia, and normalization of sleep. Among the patients of this group, by the end of the study, there were significantly more patients with complete or significant restoration of all indicators of the quality of life.